

RESEARCH ARTICLE

Pulmonary hyperinflation due to gas trapping and pulmonary artery size: The MESA COPD Study

Hooman D. Poor¹, Steven M. Kawut², Chia-Ying Liu³, Benjamin M. Smith¹, Eric A. Hoffman⁴, João A. Lima³, Bharath Ambale-Venkatesh³, Erin D. Michos⁵, Martin R. Prince⁶, R. Graham Barr^{1,7*}

1 Department of Medicine, Columbia University Medical Center, New York, New York, United States of America, **2** Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **3** Department of Radiology Johns Hopkins University, Baltimore, Maryland, United States of America, **4** Department of Radiology, University of Iowa, Iowa City, Iowa, United States of America, **5** Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, **6** Department of Radiology, Columbia University Medical Center, New York, New York, United States of America, **7** Department of Epidemiology, Columbia University Medical Center, New York, New York, United States of America

* rgb9@cumc.columbia.edu



OPEN ACCESS

Citation: Poor HD, Kawut SM, Liu C-Y, Smith BM, Hoffman EA, Lima JA, et al. (2017) Pulmonary hyperinflation due to gas trapping and pulmonary artery size: The MESA COPD Study. PLoS ONE 12(5): e0176812. <https://doi.org/10.1371/journal.pone.0176812>

Editor: Mehrdad Arjomandi, University of California San Francisco, UNITED STATES

Received: May 10, 2016

Accepted: April 18, 2017

Published: May 2, 2017

Copyright: © 2017 Poor et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: MESA data and its ancillary study data, including this study, were collected under grants and contracts from and are owned by the NIH/NHLBI. The MESA mechanism for public access to data is via the BioLINCC repository: <https://biolincc.nhlbi.nih.gov/studies/mesa/?q=MESA>. In addition to the public access repository, interested investigators may also access the data through the MESA Coordinating Center at the University of Washington by emailing Craig Johnson (wcraigj@u.washington.edu). Use of the data via this mechanism is overseen by

Abstract

Background

Pulmonary hypertension is associated with increased morbidity and mortality in chronic obstructive pulmonary disease (COPD). Since pulmonary artery (PA) size increases in pulmonary hypertension, we measured PA cross-sectional area using magnetic resonance imaging (MRI) to test the hypothesis that pulmonary hyperinflation due to gas trapping is associated with PA cross-sectional area in COPD.

Methods

The MESA COPD Study recruited participants with COPD and controls from two population-based cohort studies ages 50–79 years with 10 or more pack-years and free of clinical cardiovascular disease. Body plethysmography was performed according to standard criteria. Cardiac MRI was performed at functional residual capacity to measure the cross-sectional area of the main PA. Percent emphysema was defined as the percentage of lung voxels less than -950 Hounsfield units as assessed via x-ray computed tomography. Analyses were adjusted for age, gender, height, weight, race-ethnicity, the forced expiratory volume in one second, smoking status, pack-years, lung function, oxygen saturation, blood pressure, left ventricular ejection fraction and percent emphysema.

Results

Among 106 participants, mean residual volume was 1.98±0.71 L and the mean PA cross-sectional area was 7.23±1.72 cm². A one standard deviation increase in residual volume was independently associated with an increase in main PA cross-sectional area of 0.55 cm²

standard MESA policies and procedures, which assure that participant consents are honored and that the topic does not overlap with previously proposed or published work.

Funding: The MESA COPD Study is supported by the National Institutes of Health R01-HL093081, R01-HL077612 and R01-HL075476. MESA is supported by N01-HC95159-HC95169 and UL1-RR024156.

Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Hoffman is a founder of and owns shares in a company (Vida Diagnostics, Inc.) that has commercialized a version of the CT reading software used in this paper. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The others authors have declared that no competing interests exist.

(95% CI 0.18 to 0.92; $p = 0.003$). In contrast, there was no evidence for an association with percent emphysema or total lung capacity.

Conclusion

Increased residual volume was associated with a larger PA in COPD, suggesting that gas trapping may contribute to pulmonary hypertension in COPD.

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by accelerated age-related loss in lung function and progressive airflow obstruction that is only partially reversible [1]. COPD is the third leading cause of mortality in the United States [2]. COPD may be complicated by the development of pulmonary hypertension (PH), although the severity of PH in COPD patients is usually mild [3]. The presence of PH in COPD is associated with increased mortality [4], increased hospitalizations [5], and reduced exercise capacity [6, 7].

The gold standard to diagnose and characterize the degree of PH is right heart catheterization, a relatively safe but still invasive procedure. Echocardiographic estimates of pulmonary artery (PA) pressures are subject to significant error in patients with COPD, given the technical challenges that arise from pulmonary hyperinflation with hyperexpansion of the chest [8, 9]. PA dilatation is a consequence of PH and its presence can be used to infer PH noninvasively with various imaging modalities, including cardiac magnetic resonance imaging (MRI) [10–13]. In addition, an increased ratio of PA:aortic diameter as measured on computed tomography (CT) was associated with severe exacerbations of COPD [14].

PH in COPD is caused by a combination of factors, including alveolar hypoxia acutely causing hypoxic pulmonary vasoconstriction [15], chronically contributing to pulmonary vascular remodeling [16, 17], hypercapnia and acidosis [18, 19], along with comorbidities including obstructive sleep apnea, left ventricular systolic or diastolic dysfunction and thromboembolic disease [20]. Although increases in PA pressure can be provoked by gas trapping and lung hyperinflation during hyperventilation [21], exercise [22] and acute exacerbations [23], it is unclear whether gas trapping and hyperinflation contribute to PH in stable COPD patients. Destruction of the pulmonary vascular bed has also been hypothesized as contributing to PH in emphysema, however; there is a lack of substantial evidence to support this mechanism [20]. In the classic literature, emphysematous COPD was not characterized by PH [24] and, in a recent report from this cohort, emphysematous COPD was associated with smaller not larger right ventricular volumes [25]. Recent studies have linked early pathology associated with smoking associated emphysema to both loss of peripheral airways [26] and heterogeneous parenchymal perfusion [27].

We hypothesized that greater residual volume, a standard clinical measure of pulmonary hyperinflation and alveolar gas trapping on body plethysmography [28], would be independently associated with larger PA cross-sectional area as measured by cardiac MRI. In addition, to assess a possible confounding factor of parenchymal destruction, we also examined if the degree of emphysema-like lung (percent emphysema) on computed tomography (CT) and thoracic hyperexpansion were independently associated with PA cross-sectional area.

Materials and methods

Study participants

The MESA COPD Study is a cross-sectional study of smokers nested among the Multi-Ethnic Study of Atherosclerosis (MESA)[29] and the Emphysema and Cancer Action Project (EMCAP)[30]. Inclusion criteria were age 50–79 years old and ≥ 10 pack-year smoking history. Exclusion criteria included clinical cardiovascular disease (heart failure, valve disease, coronary artery disease, stroke, congenital heart disease or current atrial fibrillation), asthma prior to age 45 years, pulmonary embolism and other lung diseases, weight > 300 lbs, Stage III/IV chronic kidney disease insufficiency, and contraindications to MRI, gadolinium, albuterol or spirometry. This report includes the 106 participants who completed chest CT, body plethysmography and cardiac MRI.

Pulmonary function testing

A V6200 Series Autobox (SensorMedics, Yorba Linda, CA) and an OMI rolling barrel spirometer were used to perform body plethysmography and post-bronchodilator spirometry, respectively, following American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations [31, 32] and as has been previously described [33]. Functional residual capacity (FRC) was measured while panting at 0.5 to 1 breaths per second. At least two technically satisfactory maneuvers were performed, followed by an inspiratory capacity and slow vital capacity maneuver. The mean of the satisfactory measurements was used for the FRC. The total lung capacity (TLC) was calculated as the sum of the FRC and the inspiratory capacity (IC). The residual volume was calculated as the difference between the TLC and the slow vital capacity. Hankinson reference equations were used to calculate predicted spirometry values [33]. ATS/ERS COPD criteria were used to assess COPD status and severity [34]. Predicted lung volume values and upper and lower limits of normal for each lung volume were calculated using Garcia-Rio reference equations for participants 65 years and older, and Crapo reference equations for participants under 65 years [35, 36].

Gas trapping was defined as residual volume or residual volume/TLC above the upper limit of normal; hyperexpansion was defined as FRC or TLC above the upper limit of normal.[37]

Cardiac MRI and pulmonary artery cross-sectional area analysis

Cardiac MRI was performed at 1.5 Tesla (Signal LX, GE Healthcare, Waukesha, WI) using the MESA protocol as previously described [29]. An oblique localizer prescribed from axial and coronal images was used to visualize the natural curvature of the pulmonary artery. This oblique localizer was used to prescribe a plane perpendicular to the main PA positioned above the pulmonary valve but below the pulmonary bifurcation. The right PA was imaged between the trachea and the ascending aorta using a coronal localizer. A localizer oblique to the plane of the left PA was prescribed from an axial image and used for obtaining the plane perpendicular to the left PA. For main, right and left PA, phase-contrast images were obtained using a segmented gradient echo sequence (TR/TE = 7.5/3.1 msec, slice thickness 8 mm, matrix 256x256, 2 views/segment, 30 cardiac phases over the cardiac cycle, two averages, velocity encoding 100 cm/s) without breath holding. For each PA, the maximum/minimum diameter and cross-sectional areas were measured with electronic calipers (Advantage Windows Workstation, GE Healthcare, Waukesha, WI). The coefficient of variation for the inter-reader variability of the main PA measures was 6%. The maximum and minimum areas obtained of the PA during the cardiac cycle were deemed the systolic and diastolic areas respectively.

To measure left ventricular function, the entire heart was imaged in short-axis orientation with 12 or more slices. All cine images had temporal resolution of 48 msec and were retrospectively reconstructed at overlapping 20–35 msec intervals over the cardiac cycle with 40 phases. Semi-automated contouring was used to determine left ventricular volumes and ejection fraction (Cardiac Image Modeller, New Zealand) [38]. Cardiac MR readers were blinded from other participant information.

To measure the volume of the left atrium (LA), an experienced operator defined the LA endocardial and epicardial borders at the frame of the largest LA volume using the Multimodality Tissue tracking software (MTT; version 6.0, Toshiba, Japan) on long-axis 2-chamber and 4-chamber cine MR images. The volume was calculated using the biplane method as follows: LA volume = $(0.848 * \text{area4chamber} * \text{area2chamber}) / (\text{length2chamber} + \text{length4chamber}) / 2$ [39].

Assessment of percent emphysema on CT

A GE 64-slice helical scanner (120 kVp, 200mAs at 0.5 seconds) with 0.75 mm slice thickness was used to perform full-lung thoracic CT on the participants. Images were obtained at suspended full inspiration. Percent emphysema was assessed via the Apollo software (VIDA Diagnostics, Coralville IA) at a single, independent reading center blinded to other participant. The percentage of total voxels within the lung field with values below -950 Hounsfield units (HU) was designated as percent emphysema (also known as percent low attenuation areas) [40].

Anthropometry, blood pressure and other co-variates: Age, gender and race or ethnic group were self-reported. Height, weight, seated blood pressure were measured according to the MESA protocol [41]. Smoking history was self-reported using a standard questionnaire and smoking status was confirmed with plasma and urine cotinine levels (Immulite 2000 Nicotine Metabolite Assay; Diagnostic Products Corp., Los Angeles, CA, USA). Oxygen saturation was measured non-invasively at rest with pulse oximetry. Serum bicarbonate was measured on clinical chemistries.

Study oversight

The institutional review boards of the participating institutions, which include Columbia University, UCLA, Johns Hopkins, University of Iowa, Northwestern University, University of Washington, and the National Heart, Lung, and Blood Institute, approved the study procedures. Written informed consent was obtained from all participants in the MESA COPD Study.

Statistical analysis

The cohort was stratified by quartiles of percent predicted residual volume for descriptive purposes. The initial analysis of the relationship between systolic and diastolic PA cross-sectional area and residual volume was performed using multiple linear regression with adjustment for the following potential confounders and precision variables: age, gender, height, weight, race-ethnicity, FEV1, resting oxygen saturation, cohort and percent emphysema. The full model additionally included smoking history and status, blood pressure and left ventricular ejection fraction. To minimize the possibility of confounding by body size, the analyses were repeated for another measure of hyperinflation, residual volume to TLC ratio (RV/TLC). Analyses for PA cross-sectional area and percent emphysema proceeded in a similar fashion. Analyses were weighted according to the inverse ratio of sample prevalence to source study prevalence, as previously described [37], to avoid bias for the recruitment based on COPD status. To account for multiple comparisons of the two primary endpoints, systolic and diastolic cross-sectional

areas of the main PA, we used a two-tailed, Bonferroni-corrected P-value of 0.025 to define statistical significance. If significant, we additionally performed secondary analyses of the right and left PA cross-sectional areas.

Results

Of the 106 participants, the mean age was 69.5 ± 5 years and 57% were male. [Table 1](#) summarizes the characteristics of the study participants stratified by quartile of percent predicted residual volume. Sixty-five percent of the participants had COPD, mostly of mild or moderate severity. The proportion of males and current smokers increased across categories of residual volume, as did severity of COPD, alternate measures of hyperinflation and percent emphysema. Height and weight increased across categories of residual volume but BMI did not; oxygen saturation and bicarbonate were similar across categories, and left ventricular ejection fraction was marginally lower only in the category with the greatest residual volume. Twenty-seven participants (25%) had a residual volume greater than 100% predicted and 18 participants (17%) had a residual volume greater than 110% predicted.

Pulmonary hyperinflation/gas trapping and PA dimension

Both systolic and diastolic main PA cross-sectional areas rose monotonically across categories of residual volume ([Table 2](#)). A significant association was observed between residual volume, and the systolic cross-sectional area of the main PA. In the fully adjusted model, a one standard deviation increase in residual volume (0.71 L) was associated with a 0.55 cm^2 increase in the main PA systolic cross-sectional area (95% CI 0.18 to 0.92; $p = 0.003$). Results were very similar and equally significant for the main PA diastolic cross-sectional area ([Table 2](#)). We additionally examined the right and left PA: there were similar significant associations between residual volume and the right PA cross-sectional area but no association between residual volume and the left PA cross-sectional area.

Similar associations of often greater statistical significance were observed between RV/TLC and PA cross-sectional areas ([S1 Table](#)).

Additional sensitivity analyses revealed no significant interaction between these associations and gender, smoking status, cohort, presence of COPD, serum bicarbonate, left ventricular mass, left ventricular stroke volume, left ventricular end-diastolic volume. ([Fig 1](#)). When stratifying the results for with COPD, the point estimate for the effect of RV on PA cross-sectional area did not change but the confidence intervals widened, likely indicating that the study was underpowered for this subgroup and not that there was an effect modification of the relationship by COPD status.

Percent emphysema and hyperexpansion and PA dimensions

In contrast to the results for pulmonary hyperinflation and gas trapping, there was no evidence for an association between percent emphysema and any PA cross-sectional area ([Table 3](#)). There was also no evidence for an association between PA cross-sectional areas and other measures of hyperinflation suggestive of hyperexpansion, including TLC and FRC.

Right ventricular measures and PA dimensions

There was no evidence for an association between right ventricular parameters and main PA cross-sectional area. ([S2](#) and [S3](#) Tables)

Table 1. Baseline characteristics of MESA COPD Study participants with plethysmograph and MRI measures*. Stratified by quartiles percent predicted residual volume.

Characteristic	Quartiles of Percent Predicted Residual Volume			
	1	2	3	4
% Predicted Residual Volume—median No.	59% N = 26	77% N = 27	90% N = 26	120% N = 27
Age—years	70±4	71±5	71±5	67±6
Male sex—no. (%)	9 (35)	13 (48)	16 (62)	19 (70)
Race or ethnic group—no. (%)†				
Caucasian	17 (65)	23 (85)	21 (81)	20 (74)
African American	4 (15)	2 (7)	3 (12)	7 (26)
Other	5 (19)	2 (7)	2 (8)	0 (0)
Height—cm	166±10	167±10	169±8	171±10
Weight—kg	75±17	77±15	76±18	78±21
BMI—kg/m ²	27±6	27±5	27±5	26±5
Cigarette smoking status—no. (%)‡				
Former smoker	19 (73)	18 (67)	17 (65)	13 (48)
Current smoker	7 (27)	9 (33)	9 (35)	14 (52)
Pack-years of smoking—no.‡				
Median (IQR)	36 (32)	40 (25)	43 (30)	51 (34)
Serum bicarbonate—mEq/L	27 (1)	27 (2)	27 (3)	28 (3)
Blood pressure—mm Hg				
Systolic	119±18	123±15	125±18	122±14
Diastolic	67±10	69±11	73±11	74±8
COPD—no. (%)	10 (38)	13 (48)	17 (65)	25 (93)
GOLD—COPD severity—no. (%)				
Mild	5 (19)	8 (30)	8 (31)	3 (11)
Moderate	5 (19)	5 (19)	8 (31)	13 (48)
Severe / very severe	0 (0)	0 (0)	1 (4)	9 (33)
Plethysmography:				
Residual volume—L	1.24±0.23	1.69±0.16	2.08±0.23	2.89±0.66
FRC—L	2.81±0.78	2.96±0.58	3.38±0.56	4.15±0.73
% Predicted FRC	89.9±18.9	93.4±16.0	104.3±15.5	125.2±19.0
TLC—L	4.82±1.07	5.42±1.11	5.84±1.09	6.34±1.12
% Predicted TLC	85.9±11.9	93.1±10.4	96.9±9.1	102.3±12.7
Residual volume to TLC ratio	0.26±0.05	0.32±0.05	0.37±0.06	0.46±0.08
Post-bronchodilator spirometry:				
FEV ₁ —L	2.32±0.60	2.41±0.70	2.31±0.78	1.72±0.67
% Predicted FEV ₁	95.8±15.7	94.0±20.4	88.1±25.2	60.4±18.5
FVC—L	3.27±0.82	3.56±0.92	3.57±1.01	3.37±0.93
% Predicted FVC	101.8±14.9	103.9±17.8	100.7±17.9	88.1±17.9
FEV ₁ to FVC ratio	0.71 ±0.08	0.68±0.10	0.64±0.11	0.51±0.10
Diffusion capacity:				
DLCO—mL/min/mmHg	16.62±4.79	16.99±5.28	16.84±4.41	15.54±6.11
%Predicted DLCO	64.0±10.6	63.2±12.6	61.7±13.8	52.7±17.9
Percent emphysema _{0.950 HU} —median (IQR)	1.1 (2.5)	1.3 (2.6)	1.8 (2.0)	7.89 (13)
Oxygen saturation—median (IQR)	97 (3)	97 (3)	97 (3)	97 (2)
Left ventricular ejection fraction—%	61±6	61±7	63±8	59±6
Left atrial volume—mL	59.7±28.7	62.1±21.6	57.4±22.7	62.9±21.1

* Plus-minus values are means ± standard deviation.

†Race or ethnic group, smoking status and pack-year history were self-reported.

Abbreviations: COPD denotes chronic obstructive pulmonary disease, FRC functional residual capacity, TLC total lung capacity, FEV₁ forced expired volume in the first second, FVC forced vital capacity, and HU Hounsfield units.

<https://doi.org/10.1371/journal.pone.0176812.t001>

Table 2. Relationship between residual volume and pulmonary artery cross-sectional area*.

Pulmonary Artery	Mean difference in quartiles of Residual Volume				Mean difference in pulmonary artery cross-sectional area per standard deviation increase in RV (95% CI) n = 106	P Value
	59%	77%	90%	120%		
% Predicted Residual Volume—median						
Main Pulmonary Artery Systolic—cm ²	6.6 ±1.6	7.1 ±1.2	7.4 ±2.2	7.8 ±1.7		
Model 1	0	0.33	0.53	0.64	0.43 (-0.01 to 0.86)	0.055
Model 2	0	0.38	0.85	0.82	0.55 (0.18 to 0.92)	0.003
Main Pulmonary Artery Diastolic—cm ²	5.8 ±1.4	6.2 ±1.1	6.5 ±2.0	7.0 ±1.6		
Model 1	0	0.37	0.45	0.56	0.38 (-0.01 to 0.78)	0.059
Model 2	0	0.41	0.75	0.71	0.51 (0.12 to 0.90)	0.01
Right Pulmonary Artery Systolic—cm ²	3.8 ±1.0	4.7 ±0.8	4.7 ±1.2	5.1 ±1.4		
Model 1	0	1.20	0.96	1.83	0.63 (0.16 to 1.11)	0.009
Model 2	0	1.22	1.00	1.82	0.66 (0.21 to 1.12)	0.004
Right Pulmonary Artery Diastolic—cm ²	3.2 ±0.8	4.0 ±0.8	3.9 ±1.0	4.3 ±1.2		
Model 1	0	1.03	0.77	1.60	0.55 (0.12 to 0.98)	0.01
Model 2	0	1.02	0.75	1.56	0.56 (0.16 to 0.97)	0.006
Left Pulmonary Artery Systolic—cm ²	4.1 ±1.0	4.1 ±1.2	4.2 ±1.3	4.8 ±1.5		
Model 1	0	0.30	-0.30	0.18	-0.24 (-0.73 to 0.25)	0.34
Model 2	0	0.25	-0.54	0.13	-0.30 (-0.76 to 0.15)	0.19
Left Pulmonary Artery Diastolic—cm ²	3.6 ±1.0	3.5 ±1.0	3.6 ±1.1	4.1 ±1.3		
Model 1	0	0.15	-0.38	0.05	-0.26 (-0.70 to 0.18)	0.25
Model 2	0	0.10	-0.60	-0.01	-0.31 (-0.70 to 0.08)	0.12

*Mean differences in model 1 were adjusted for age, gender, race or ethnic group, height, weight, cohort, percent emphysema_{950 HU}, forced expired volume in the first second and oxygen saturation. Model 2 was additionally adjusted for smoking status, pack-years of smoking history, systolic blood pressure, diastolic blood pressure and left ventricular ejection fraction. Plus-minus values are means ± standard deviation. Abbreviations: CI denotes confidence interval, HU Hounsfield units, RV residual volume and FEV₁ forced expired volume in the first second.

<https://doi.org/10.1371/journal.pone.0176812.t002>

Discussion

Pulmonary hyperinflation and specifically gas trapping, as assessed by increased residual volume and residual volume to TLC ratio, was associated with a larger main PA cross-sectional area on MRI. In contrast, there was no evidence that the extent of emphysema as measured by CT or measures of hyperexpansion (increased FRC and TLC) were associated with PA dimensions. These findings suggest that gas trapping, but not emphysema, are associated with pulmonary vascular remodeling in current and former smokers.

The present report is the first, to the best of our knowledge, to consider the relationship between pulmonary hyperinflation, gas trapping and PA size. A few prior studies have shown a relationship between pulmonary hyperinflation and increased PA pressure. The classic experiments by West elucidated the relationship between alveolar pressure and regional pulmonary blood flow, demonstrating that increasing alveolar pressure in the presence of constant pulmonary arterial pressure results in decreasing regional pulmonary blood flow. These experiments helped define the concept of the “West lung zones” [42]. Hakim and colleagues,




Fig 1. Mean difference in systolic main pulmonary artery cross-sectional area by residual volume. Original model was adjusted for age, gender, race or ethnic group, height, weight, cohort, percent emphysema_{950 HU}, forced expired volume in the first second and oxygen saturation, smoking status, pack-years of smoking history, systolic blood pressure, diastolic blood pressure and left ventricular ejection fraction.

<https://doi.org/10.1371/journal.pone.0176812.g001>

using a canine model, determined that pulmonary vascular resistance increases with lung inflation, both via positive-pressure and negative-pressure breathing, suggesting that alveolar vessels behave as Starling resistors [43]. Fuld et al., utilizing both dynamic computed tomography to directly assess pulmonary perfusion and dual energy CT to assess regional pulmonary blood volume, demonstrated the role of increasing lung volume in limiting both perfusion and regional blood volume in the non-dependent lung regions with the extent of the effect increasing with the level of lung inflation [44]. The association between increased PA cross-sectional area and hyperinflation with gas trapping found in our study may be a result of the compression of alveolar vessels from increased alveolar pressure and volume, leading to an increase in pulmonary vascular resistance and consequently an increase in PA pressure. While a similar association between PA pressure and hyperinflation with gas trapping was found for the right PA, there was no association for the left PA. This discrepancy may have occurred because the right PA is less constrained by mediastinal structures than the left PA, possibly making its cross-sectional area a better gauge of intravascular pressure.

The effect of gas trapping and hyperinflation on PA pressure and pulmonary vascular resistance in patients with COPD has been previously studied in small but interventional studies. Harris and colleagues reported that voluntary hyperventilation to achieve high minute ventilation in patients with chronic bronchitis resulted in increased PA pressures and increased pulmonary vascular resistance but that it had no such effect in normal patients [45]. Similarly, Butler and colleagues found an increase in PA pressure and pulmonary capillary wedge pressure with hyperventilation in patients with COPD but not in normal patients [21]. In a recent study examining explanted lungs from 17 patients with severe COPD, half of them with mild pulmonary hypertension, pulmonary vascular involvement was unexpectedly modest,

Table 3. Relationship between percent emphysema and pulmonary artery cross-sectional area*.

<i>Pulmonary Artery</i>	<i>Mean difference in pulmonary artery cross-sectional area per standard deviation increase in log-transform percent emphysema (95% CI)</i>	<i>P Value</i>
Main Pulmonary Artery Systolic—cm ²		
Model 1	0.02 (-0.23 to 0.27)	0.85
Model 2	0.02 (-0.24 to 0.28)	0.88
Main Pulmonary Artery Diastolic—cm ²		
Model 1	0.06 (-0.17 to 0.29)	0.60
Model 2	0.08 (-0.15 to 0.31)	0.49
Right Pulmonary Artery Systolic—cm ²		
Model 1	-0.01 (-0.18 to 0.15)	0.88
Model 2	0.002 (-0.16 to 0.17)	0.98
Right Pulmonary Artery Diastolic—cm ²		
Model 1	0.02 (-0.12 to 0.17)	0.75
Model 2	0.05 (-0.91 to 0.19)	0.50
Left Pulmonary Artery Systolic—cm ²		
Model 1	0.08 (-0.10 to 0.27)	0.38
Model 2	0.11 (-0.07 to 0.29)	0.24
Left Pulmonary Artery Diastolic—cm ²		
Model 1	0.09 (-0.08 to 0.25)	0.31
Model 2	0.12 (-0.05 to 0.28)	0.16

*Mean differences in model 1 were adjusted for age, gender, race or ethnic group, height, weight, cohort, forced expired volume in the first second and oxygen saturation. Model 2 was additionally adjusted for smoking status, pack-years of smoking history, systolic blood pressure, diastolic blood pressure and left ventricular ejection fraction. Abbreviations: CI denotes confidence interval.

<https://doi.org/10.1371/journal.pone.0176812.t003>

indicating a mechanism other than a primary vasculopathy as the cause of pulmonary hypertension [46]. These studies suggest that dynamic hyperinflation may be the major contributor to hemodynamic changes.

It has been postulated that emphysematous destruction of the pulmonary vasculature contributes to elevated pulmonary vascular pressures in COPD [47]. However, our study found no association between the extent of emphysema as measured quantitatively on CT and PA cross-sectional area. Our finding is consistent with prior studies examining the relationship between PA pressures and the extent of emphysema. Scharf and colleagues found no association between mean PA pressures and CT emphysema scores in the 120 patients with severe emphysema from the National Emphysema Treatment trial [48]. Biernacki and colleagues found no association between mean PA pressures, both at rest and with exercise, and CT measures of emphysema in 32 patients with COPD.[49] Burrows and colleagues, in their classic paper examining the different hemodynamic phenotypes in COPD, noted that patients with a predominantly “emphysematous” type of COPD often had PA pressures within normal limits and only slight elevations in pulmonary vascular resistance [24]. Furthermore, we recently

reported that COPD and particularly emphysema was associated, on average, with smaller right ventricular volumes and that this was particularly true for emphysema [25]. Of note, the association of gas trapping with increased PA dimensions reported here did not translate into right ventricular enlargement, possibly related to the generally mild-moderate severity of gas trapping in this cohort.

The present findings and above studies suggest that impaired left ventricular filling and concomitant reductions in stroke volume related to percent emphysema, which have been previously observed in a large, population-based cohort free of clinical cardiovascular disease [50] and in the present cohort [51], may be related to vascular destruction in emphysema that reduces pulmonary blood flow but which does not markedly increase PA pressure.

The present study has several limitations. First, because pulmonary cross-sectional area was measured rather than PA pressure, the proposed mechanism of increased PA pressure from downstream alveolar vessel compression leading to PA dilatation remains speculative. Conceivably, hyperinflation could cause architectural changes of the pulmonary vasculature leading to an increase in PA cross-sectional area without necessarily an increase in PA pressure. The testing necessary to demonstrate whether the increased PA cross-sectional area is from increased PA pressure or another cause are too invasive to be applied to a population-based study of participants free of clinical cardiovascular disease with predominantly mild to moderate COPD. Further work is needed to elucidate the direct relationship between hyperinflation and PA pressure by directly measuring or estimating PA pressures in patients with mild to moderate COPD. Second, residual confounding by left ventricular diastolic dysfunction may have contributed to the observed association. Smith and colleagues, in the same cohort as this study, observed that greater residual volume and RV/TLC ratio is associated with greater left ventricular mass [37]. However, in our study, sensitivity analyses revealed no effect when adjusting for left ventricular end-diastolic mass, left ventricular end-diastolic volume and left ventricular stroke volume. Third, we did not perform arterial blood gasses; however, there was no suggestion that hypoxemia and hypercapnea varied substantially with residual volume in this cohort and sensitivity analyses revealed no effect when adjusting for serum bicarbonate. Fourth, the cross-sectional design of the study does not allow for determination of cause and effect for the observed association; however, it seems much more likely from a physiologic standpoint that hyperinflation would cause increased PA cross-sectional area as opposed to the other way around.

Conclusions

In conclusion, increased residual volume, a measure of pulmonary hyperinflation and gas trapping, was independently associated with increased PA cross-sectional area. In contrast, there was no evidence of a relationship of emphysema severity to PA dimensions. These results suggest that gas trapping may be a cause of increased PA pressure in COPD, possibly from alveolar vessel compression by distended alveoli.

Supporting information

S1 Table. Relationship between residual volume–Total lung capacity ratio and pulmonary artery cross-sectional area. Mean differences in model 1 were adjusted for age, gender, race or ethnic group, height, weight, cohort, percent emphysema_{-950 HU}, forced expired volume in the first second and oxygen saturation. Model 2 was additionally adjusted for smoking status, pack-years of smoking history, systolic blood pressure, diastolic blood pressure and left ventricular ejection fraction. Abbreviations: CI denotes confidence interval, HU Hounsfield units,

RV residual volume, TLC total lung capacity and FEV₁ forced expired volume in the first second.

(DOCX)

S2 Table. Relationship between right ventricle parameters and main pulmonary artery systolic cross-sectional area. Models were adjusted for age, gender, race or ethnic group, height, weight, cohort, percent emphysema_{.950 HU}, forced expired volume in the first second, oxygen saturation, smoking status, pack-years of smoking history, systolic blood pressure, and diastolic blood pressure. Abbreviations: CI denotes confidence interval, HU Hounsfield units, RV right ventricle.

(DOCX)

S3 Table. Relationship between right ventricle parameters and main pulmonary artery diastolic cross-sectional area. Models were adjusted for age, gender, race or ethnic group, height, weight, cohort, percent emphysema_{.950 HU}, forced expired volume in the first second, oxygen saturation, smoking status, pack-years of smoking history, systolic blood pressure, and diastolic blood pressure. Abbreviations: CI denotes confidence interval, HU Hounsfield units, RV right ventricle.

(DOCX)

Author Contributions

Conceptualization: HP SK CYL BS BA EH JL EM MP RGB.

Data curation: HP SK CYL BS BA EH JL EM MP RGB.

Formal analysis: HP BS RGB.

Funding acquisition: RGB.

Methodology: CYL BA MP.

Project administration: RGB.

Supervision: RGB.

Writing – original draft: HP.

Writing – review & editing: HP SK CYL BS BA EH JL EM MP RGB.

References

1. Decramer M, Janssens W, Miravittles M. Chronic obstructive pulmonary disease. *Lancet*. 2012; 379 (9823):1341–51. Epub 2012/02/09. [https://doi.org/10.1016/S0140-6736\(11\)60968-9](https://doi.org/10.1016/S0140-6736(11)60968-9) PMID: 22314182
2. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_02.pdf
3. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. *Chest*. 2010; 137(6 Suppl):39S–51S. Epub 2010/06/11. <https://doi.org/10.1378/chest.10-0087> PMID: 20522579
4. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. *Chest*. 1995; 107(5):1193–8. Epub 1995/05/01. PMID: 7750305
5. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 1999; 159(1):158–64. Epub 1999/01/05. <https://doi.org/10.1164/ajrccm.159.1.9803117> PMID: 9872834

6. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. *Chest*. 2009; 136(2):412–9. Epub 2009/03/26. <https://doi.org/10.1378/chest.08-2739> PMID: 19318664
7. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, et al. Ventilatory and cardio-circulatory exercise profiles in COPD: the role of pulmonary hypertension. *Chest*. 2012. Epub 2012/05/05.
8. Fisher MR, Criner GJ, Fishman AP, Hassoun PM, Minai OA, Scharf SM, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. *The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology*. 2007; 30(5):914–21. Epub 2007/07/27.
9. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *American journal of respiratory and critical care medicine*. 2003; 167(5):735–40. Epub 2002/12/14. <https://doi.org/10.1164/rccm.200210-1130OC> PMID: 12480614
10. Sanz J, Kuschnir P, Rius T, Salguero R, Sulica R, Einstein AJ, et al. Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging. *Radiology*. 2007; 243(1):70–9. Epub 2007/03/03. <https://doi.org/10.1148/radiol.2431060477> PMID: 17329691
11. Sanz J, Kariisa M, Dellegrottaglie S, Prat-Gonzalez S, Garcia MJ, Fuster V, et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. *JACC Cardiovascular imaging*. 2009; 2(3):286–95. Epub 2009/04/10. <https://doi.org/10.1016/j.jcmg.2008.08.007> PMID: 19356573
12. Boerrigter B, Mauritz GJ, Marcus JT, Helderma F, Postmus PE, Westerhof N, et al. Progressive dilatation of the main pulmonary artery is a characteristic of pulmonary arterial hypertension and is not related to changes in pressure. *Chest*. 2010; 138(6):1395–401. Epub 2010/05/25. <https://doi.org/10.1378/chest.10-0363> PMID: 20495109
13. Frank H, Globits S, Glogar D, Neuhold A, Kneussl M, Mlczoch J. Detection and quantification of pulmonary artery hypertension with MR imaging: results in 23 patients. *AJR American journal of roentgenology*. 1993; 161(1):27–31. Epub 1993/07/01. <https://doi.org/10.2214/ajr.161.1.8517315> PMID: 8517315
14. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. *The New England journal of medicine*. 2012; 367(10):913–21. Epub 2012/09/04. <https://doi.org/10.1056/NEJMoa1203830> PMID: 22938715
15. Hales CA. The site and mechanism of oxygen sensing for the pulmonary vessels. *Chest*. 1985; 88(4 Suppl):235S–40S. Epub 1985/10/01. PMID: 4042729
16. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. *Circulation research*. 2006; 99(7):675–91. Epub 2006/09/30. <https://doi.org/10.1161/01.RES.0000243584.45145.3f> PMID: 17008597
17. Penalzoza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. *Circulation*. 2007; 115(9):1132–46. Epub 2007/03/07. <https://doi.org/10.1161/CIRCULATIONAHA.106.624544> PMID: 17339571
18. Balanos GM, Talbot NP, Dorrington KL, Robbins PA. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. *J Appl Physiol*. 2003; 94(4):1543–51. Epub 2002/12/17. <https://doi.org/10.1152/jappphysiol.00890.2002> PMID: 12482766
19. Mekontso Dessap A, Charron C, Devaquet J, Aboab J, Jardin F, Brochard L, et al. Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. *Intensive care medicine*. 2009; 35(11):1850–8. Epub 2009/08/05. <https://doi.org/10.1007/s00134-009-1569-2> PMID: 19652953
20. Wrobel JP, Thompson BR, Williams TJ. Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review. *The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation*. 2012; 31(6):557–64. Epub 2012/04/17.
21. Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. *The American review of respiratory disease*. 1988; 138(2):350–4. Epub 1988/08/01. <https://doi.org/10.1164/ajrccm/138.2.350> PMID: 3195834
22. Schrijen FV, Henriquez A, Carton D, Delorme N, Butler J. Pulmonary vascular resistance rises with lung volume on exercise in obstructed airflow disease. *Clin Physiol*. 1989; 9(2):143–50. Epub 1989/04/01. PMID: 2721127
23. Akcay M, Yeter E, Durmaz T, Keles T, Akar Bayram N, Uyar M, et al. Treatment of acute chronic obstructive pulmonary disease exacerbation improves right ventricle function. *European journal of echocardiography: the journal of the Working Group on Echocardiography of the European Society of Cardiology*. 2010; 11(6):530–6. Epub 2010/03/13.

24. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. *The New England journal of medicine*. 1972; 286(17):912–8. <https://doi.org/10.1056/NEJM197204272861703> PMID: 5013974
25. Kawut SM, Poor HD, Parikh MA, Hueper K, Smith BM, Bluemke DA, et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. *Journal of the American College of Cardiology*. 2014; 64(19):2000–9. <https://doi.org/10.1016/j.jacc.2014.07.991> PMID: 25440095
26. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *The New England journal of medicine*. 2011; 365(17):1567–75. <https://doi.org/10.1056/NEJMoa1106955> PMID: 22029978
27. Alford SK, van Beek EJ, McLennan G, Hoffman EA. Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(16):7485–90. <https://doi.org/10.1073/pnas.0913880107> PMID: 20368443
28. Leith DE, Brown R. Human lung volumes and the mechanisms that set them. *The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology*. 1999; 13(2):468–72. Epub 1999/03/05.
29. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis: objectives and design. *American journal of epidemiology*. 2002; 156(9):871–81. Epub 2002/10/25. PMID: 12397006
30. Mesia-Vela S, Yeh CC, Austin JH, Dounel M, Powell CA, Reeves A, et al. Plasma carbonyls do not correlate with lung function or computed tomography measures of lung density in older smokers. *Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals*. 2008; 13(4):422–34. Epub 2008/05/20.
31. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. *The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology*. 2005; 26(3):511–22. Epub 2005/09/02.
32. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology*. 2005; 26(2):319–38. Epub 2005/08/02.
33. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. *Chest*. 2010; 137(1):138–45. Epub 2009/09/11. <https://doi.org/10.1378/chest.09-0919> PMID: 19741060
34. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology*. 2004; 23(6):932–46. Epub 2004/06/29.
35. Garcia-Rio F, Dorgham A, Pino JM, Villasante C, Garcia-Quero C, Alvarez-Sala R. Lung volume reference values for women and men 65 to 85 years of age. *American journal of respiratory and critical care medicine*. 2009; 180(11):1083–91. <https://doi.org/10.1164/rccm.200901-0127OC> PMID: 19745204
36. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. *Bulletin europeen de physiopathologie respiratoire*. 1982; 18(3):419–25. Epub 1982/05/01. PMID: 7074238
37. Smith BM, Kawut SM, Bluemke DA, Basner RC, Gomes AS, Hoffman E, et al. Pulmonary Hyperinflation and Left Ventricular Mass: The Multi-Ethnic Study of Atherosclerosis COPD Study. *Circulation*. 2013; 127(14):1503–11. Epub 2013/03/16. <https://doi.org/10.1161/CIRCULATIONAHA.113.001653> PMID: 23493320
38. Young AA, Cowan BR, Thrupp SF, Hedley WJ, Dell'Italia LJ. Left ventricular mass and volume: fast calculation with guide-point modeling on MR images. *Radiology*. 2000; 216(2):597–602. Epub 2000/08/05. <https://doi.org/10.1148/radiology.216.2.r00au14597> PMID: 10924592
39. Zareian M, Ciuffo L, Habibi M, Opdahl A, Chamera EH, Wu CO, et al. Left atrial structure and functional quantitation using cardiovascular magnetic resonance and multimodality tissue tracking: validation and reproducibility assessment. *J Cardiovasc Magn Reson*. 2015; 17:52. <https://doi.org/10.1186/s12968-015-0152-y> PMID: 26126732
40. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. *American journal of respiratory and critical care medicine*. 1995; 152(2):653–7. Epub 1995/08/01. <https://doi.org/10.1164/ajrccm.152.2.7633722> PMID: 7633722
41. Exam 5 Field Center Procedures Manual of Operations. MESA—NHLBI, 2010. (Accessed April 26, 2012, 2012, at http://www.mesa-nhlbi.org/publicdocs/2011/mesae5_mopjanuary2011.pdf

42. West JB, Dollery CT, Naimark A. Distribution of Blood Flow in Isolated Lung; Relation to Vascular and Alveolar Pressures. *J Appl Physiol*. 1964; 19:713–24. Epub 1964/07/01. PMID: [14195584](#)
43. Hakim TS, Michel RP, Chang HK. Effect of lung inflation on pulmonary vascular resistance by arterial and venous occlusion. *J Appl Physiol*. 1982; 53(5):1110–5. Epub 1982/11/01. PMID: [6757207](#)
44. Fuld MK, Halaweish AF, Haynes SE, Divekar AA, Guo J, Hoffman EA. Pulmonary perfused blood volume with dual-energy CT as surrogate for pulmonary perfusion assessed with dynamic multidetector CT. *Radiology*. 2013; 267(3):747–56. <https://doi.org/10.1148/radiol.12112789> PMID: [23192773](#)
45. Harris P, Segel N, Green I, Housley E. The influence of the airways resistance and alveolar pressure on the pulmonary vascular resistance in chronic bronchitis. *Cardiovascular research*. 1968; 2(1):84–92. Epub 1968/01/01. PMID: [5645469](#)
46. Peinado VI, Gomez FP, Barbera JA, Roman A, Angels Montero M, Ramirez J, et al. Pulmonary vascular abnormalities in chronic obstructive pulmonary disease undergoing lung transplant. *The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation*. 2013; 32(12):1262–9.
47. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 2005; 172(2):189–94. Epub 2005/04/16. <https://doi.org/10.1164/rccm.200401-006OC> PMID: [15831842](#)
48. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. *American journal of respiratory and critical care medicine*. 2002; 166(3):314–22. Epub 2002/08/03. <https://doi.org/10.1164/rccm.2107027> PMID: [12153963](#)
49. Biernacki W, Gould GA, Whyte KF, Flenley DC. Pulmonary hemodynamics, gas exchange, and the severity of emphysema as assessed by quantitative CT scan in chronic bronchitis and emphysema. *The American review of respiratory disease*. 1989; 139(6):1509–15. Epub 1989/06/01. <https://doi.org/10.1164/ajrccm/139.6.1509> PMID: [2729756](#)
50. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *The New England journal of medicine*. 2010; 362(3):217–27. Epub 2010/01/22. <https://doi.org/10.1056/NEJMoa0808836> PMID: [20089972](#)
51. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D, et al. Impaired Left Ventricular Filling in COPD and Emphysema: Is It the Heart or the Lungs?: The Multi-Ethnic Study of Atherosclerosis COPD Study. *Chest*. 2013; 144(4):1143–51. <https://doi.org/10.1378/chest.13-0183> PMID: [23764937](#)